

PATENT
ATTORNEY DOCKET NO. 045636-5037

#7
PL
11.30.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Guy SERRE et al.)	
)	
Application No.: Unassigned)	Group Art Unit: Unassigned
)	
Date of National Stage Entry: June 30, 2000)	
)	Examiner: Unassigned
Based on: PCT/FR98/02899)	
)	
Filed: December 29, 1998)	
)	
For: PEPTIDE EPITOPES RECOGNIZED BY)	
ANTI-FILAGGRIN AUTO-ANTIBODIES)	
IN SERUM FROM RHEUMATOID)	
ARTHRITIS PATIENTS)	

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed within three months of the date of the National Stage entry of the above-referenced application. Accordingly, Applicants do not believe that a fee is due for filing this paper.

A copy of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

An International Search Report, citing the documents and setting forth the relevance thereof are also enclosed for the Examiner's consideration. In addition to this citation the relevance of French language document WO 98/08946 is noted on page 4, lines 21-32, of the specification, which cites the French priority document of this publication.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If it should be determined that the listed documents do constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No.

50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR
EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Elizabeth C. Weimar
Reg. No. 44.478

Dated: June 30, 2000

MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036-5869
(202) 467-7000